EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 (Novembre 2023) Hors série n° 1 Med Sci (Paris), 39 (2023) 6-10 References
Free Access
Issue
Med Sci (Paris)
Volume 39, Novembre 2023
Les Cahiers de Myologie
Page(s) 6 - 10
Section Mise au point
DOI https://doi.org/10.1051/medsci/2023130
Published online 17 November 2023
  1. SpiroAJ, ShyGM, GonatasNK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966 ; 14 : 1–14. [CrossRef] [PubMed] [Google Scholar]
  2. LaporteJ, HuLJ, KretzC, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996 ; 13 : 175–182. [CrossRef] [PubMed] [Google Scholar]
  3. Laporte J, Bedez F, Bolino A, et al. Myotubularins, a large disease-associated family of cooperating catalytically active and inactive phosphoinositides phosphatases. Hum Mol Genet 2003; 12 (spécial n° 2) : R285–92. [CrossRef] [PubMed] [Google Scholar]
  4. NicotAS, ToussaintA, ToschV, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007 ; 39 : 1134–1139. [CrossRef] [PubMed] [Google Scholar]
  5. BohmJ, BiancalanaV, MalfattiE, et al. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain 2014 ; 137 : 3160–3170. [CrossRef] [PubMed] [Google Scholar]
  6. ToschV, RohdeHM, TronchereH, et al. A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Hum Mol Genet 2006 ; 15 : 3098–3106. [CrossRef] [PubMed] [Google Scholar]
  7. BevilacquaJA, MonnierN, BitounM, et al. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalisation and large areas of myofibrillar disorganisation. Neuropathol Appl Neurobiol 2011 ; 37 : 271–284. [CrossRef] [PubMed] [Google Scholar]
  8. JungbluthH, ZhouH, SewryCA, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2007 ; 17 : 338–345. [CrossRef] [PubMed] [Google Scholar]
  9. AgrawalPB, PiersonCR, JoshiM, et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet 2014 ; 95 : 218–226. [CrossRef] [PubMed] [Google Scholar]
  10. Ceyhan-BirsoyO, AgrawalPB, HidalgoC, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 2013 ; 81 : 1205–1214. [CrossRef] [PubMed] [Google Scholar]
  11. BohmJ, BiancalanaV, DecheneET, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012 ; 33 : 949–959. [CrossRef] [PubMed] [Google Scholar]
  12. BitounM, MaugenreS, JeannetPY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005 ; 37 : 1207–1209. [CrossRef] [PubMed] [Google Scholar]
  13. FischerD, HerasseM, BitounM, et al. Characterization of the muscle involvement in dynamin 2- related centronuclear myopathy. Brain 2006 ; 129 : 1463–1469. [CrossRef] [PubMed] [Google Scholar]
  14. HanischF, MullerT, DietzA, et al. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. J Neurol 2011 ; 258 : 1085–1090. [CrossRef] [PubMed] [Google Scholar]
  15. BitounM, BevilacquaJA, PrudhonB, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007 ; 62 : 666–670. [CrossRef] [PubMed] [Google Scholar]
  16. SusmanRD, Quijano-RoyS, YangN, et al. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscul Disord 2010 ; 20 : 229–237. [CrossRef] [PubMed] [Google Scholar]
  17. JungbluthH, CullupT, LillisS, et al. Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation. Neuromuscul Disord 2010 ; 20 : 49–52. [CrossRef] [PubMed] [Google Scholar]
  18. MelbergA, KretzC, KalimoH, et al. Adult course in dynamin 2 dominant centronuclear myopathy with neonatal onset. Neuromuscul Disord 2010 ; 20 : 53–56. [CrossRef] [PubMed] [Google Scholar]
  19. BitounM, BevilacquaJA, EymardB, et al. A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation. Neurology 2009 ; 72 : 93–95. [CrossRef] [PubMed] [Google Scholar]
  20. Gómez-Oca R, Cowling BS, Laporte J. Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances. IJMS 2021; 22 : 11377. [CrossRef] [Google Scholar]
  21. DurieuxAC, PrudhonB, GuicheneyP, et al. Dynamin 2 and human diseases. J Mol Med 2010 ; 88 : 339–350. [CrossRef] [PubMed] [Google Scholar]
  22. ZuchnerS, NoureddineM, KennersonM, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005 ; 37 : 289–294. [CrossRef] [PubMed] [Google Scholar]
  23. SambuughinN, GoldfarbLG, SivtsevaTM, et al. Adult-onset autosomal dominant spastic paraplegia linked to a GTPase-effector domain mutation of dynamin 2. BMC Neurol 2015 ; 15 : 223. [CrossRef] [PubMed] [Google Scholar]
  24. KoutsopoulosOS, KretzC, WellerCM, et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. Eur J Hum Genet 2013 ; 21 : 637–642. [CrossRef] [PubMed] [Google Scholar]
  25. Echaniz-LagunaA, NicotAS, CarreS, et al. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation. Neuromuscul Disord 2007 ; 17 : 955–959. [CrossRef] [PubMed] [Google Scholar]
  26. KierdaszukB, BerdynskiM, KarolczakJ, et al. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy. Neuromuscul Disord 2013 ; 23 : 219–228. [CrossRef] [PubMed] [Google Scholar]
  27. CowlingBS, ChevremontT, ProkicI, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest 2014 ; 124 : 1350–1363. [CrossRef] [PubMed] [Google Scholar]
  28. CowlingBS, ToussaintA, AmoasiiL, et al. Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness. Am J Pathol 2011 ; 178 : 2224–2235. [CrossRef] [PubMed] [Google Scholar]
  29. WangL, BarylkoB, ByersC, et al. Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers. J Biol Chem 2010 ; 285 : 22753–22757. [CrossRef] [PubMed] [Google Scholar]
  30. KennistonJA, LemmonMA. Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. EMBO J 2010 ; 29 : 3054–3067. [CrossRef] [PubMed] [Google Scholar]
  31. JamesNG, DigmanMA, RossJA, et al. A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes in cells. Biochim Biophys Acta 2014 ; 1840 : 315–321. [CrossRef] [Google Scholar]
  32. FaelberK, GaoS, HeldM, et al. Oligomerization of dynamin superfamily proteins in health and disease. Prog Mol Biol Transl Sci 2013 ; 117 : 411–443. [CrossRef] [PubMed] [Google Scholar]
  33. DurieuxAC, VignaudA, PrudhonB, et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010 ; 19 : 4820–4836. [CrossRef] [PubMed] [Google Scholar]
  34. FraysseB, DesaphyJF, RollandJF, et al. Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone. Neurobiol Dis 2006 ; 21 : 372–380. [CrossRef] [PubMed] [Google Scholar]
  35. GibbsEM, ClarkeNF, RoseK, et al. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med (Berl) 2013 ; 91 : 727–737. [CrossRef] [PubMed] [Google Scholar]
  36. BragatoC, GaudenziG, BlasevichF, et al. Zebrafish as a model to investigate Dynamin 2-related diseases. Sci Rep 2016 ; 6 : 20466. [CrossRef] [PubMed] [Google Scholar]
  37. KutchukianC, SzentesiP, AllardB, et al. Impaired excitation-contraction coupling in muscle fibres from the dynamin2(R465W) mouse model of centronuclear myopathy. J Physiol 2017 ; 595 : 7369–7382. [CrossRef] [PubMed] [Google Scholar]
  38. FongyA, FalconeS, LaineJ, et al. Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model. Sci Rep 2019 ; 9 : 1580. [CrossRef] [PubMed] [Google Scholar]
  39. F Almeida C, Bitoun M, Vainzof M. Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy. FASEB J 2021; 35 : e21346. [CrossRef] [PubMed] [Google Scholar]
  40. DurieuxAC, VassilopoulosS, LaineJ, et al. A centronuclear myopathy - dynamin 2 mutation impairs autophagy in mice. Traffic 2012 ; 13 : 869–879. [CrossRef] [PubMed] [Google Scholar]
  41. Puri C, Manni MM, Vicinanza M, et al. A DNM2 Centronuclear myopathy mutation reveals a link between recycling endosome scission and autophagy. Dev Cell 2020; 53 : 154–68.e6. [CrossRef] [PubMed] [Google Scholar]
  42. Gonzalez-JamettAM, Baez-MatusX, OlivaresMJ, et al. Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells. Sci Rep 2017 ; 7 : 4580. [CrossRef] [PubMed] [Google Scholar]
  43. FranckA, LaineJ, MoulayG, et al. Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. Mol Biol Cell 2019 ; 30 : 579–590. [CrossRef] [PubMed] [Google Scholar]
  44. RomeroNB, BitounM. Centronuclear myopathies. Semin Pediatr Neurol 2011 ; 18 : 250–256. [CrossRef] [PubMed] [Google Scholar]
  45. Muñoz XM, Kretz C, Silva-Rojas R, et al. Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin. JCI Insight 2020; 5 : e137899. [CrossRef] [PubMed] [Google Scholar]
  46. ZanoteliE, VerganiN, CamposY, et al. Mitochondrial alterations in dynamin 2-related centronuclear myopathy. Arq Neuropsiquiatr 2009 ; 67 : 102–104. [CrossRef] [PubMed] [Google Scholar]
  47. BitounM, DurieuxAC, PrudhonB, et al. Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. Hum Mutat 2009 ; 30 : 1419–1427. [CrossRef] [PubMed] [Google Scholar]
  48. ShevchukAI, NovakP, TaylorM, et al. An alternative mechanism of clathrin-coated pit closure revealed by ion conductance microscopy. J Cell Biol 2012 ; 197 : 499–508. [CrossRef] [PubMed] [Google Scholar]
  49. SidiropoulosPN, MieheM, BockT, et al. Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination. Brain 2012 ; 135 : 1395–1411. [CrossRef] [PubMed] [Google Scholar]
  50. LiuYW, LukiyanchukV, SchmidSL. Common membrane trafficking defects of disease-associated dynamin 2 mutations. Traffic 2011 ; 12 : 1620–1633. [CrossRef] [PubMed] [Google Scholar]
  51. TrochetD, PrudhonB, JolletA, et al. Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing. Mol Ther Nucleic Acids 2016 ; 5 : e362. [CrossRef] [PubMed] [Google Scholar]
  52. TrochetD, PrudhonB, BeuvinM, et al. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy. EMBO Mol Med 2018 ; 10 : 239–253. [CrossRef] [PubMed] [Google Scholar]
  53. Trochet D, Prudhon B, Mekzine L, et al. Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy. Mol Ther Nucleic Acids 2022; 27 : 1179–90. [CrossRef] [PubMed] [Google Scholar]
  54. RabaiA, ReisserL, Reina-San-MartinB, et al. Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation rescues centronuclear myopathy cell phenotypes. Mol Ther Nucleic Acids 2019 ; 16 : 246–256. [CrossRef] [PubMed] [Google Scholar]
  55. BuonoS, RossJA, TasfaoutH, et al. Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy. Proc Natl Acad Sci USA 2018 ; 115 : 11066–11071. [CrossRef] [PubMed] [Google Scholar]
  56. Lionello VM, Kretz C, Edelweiss E, et al. BIN1 modulation in vivo rescues dynamin-related myopathy. Proc Natl Acad Sci USA 2022; 119 : e2109576119. [CrossRef] [PubMed] [Google Scholar]
  57. CowlingBS, ProkicI, TasfaoutH, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest 2017 ; 127 : 4477–4487. [CrossRef] [PubMed] [Google Scholar]
  58. TasfaoutH, BuonoS, GuoS, et al. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun 2017 ; 8 : 15661. [CrossRef] [PubMed] [Google Scholar]
  59. TasfaoutH, LionelloV, KretzCM, et al. Single intramuscular injection of AAV-shRNA reduces DNM2 and prevents myotubular myopathy in mice. Mol Ther 2018 ; 26 : 1082–1092. [CrossRef] [PubMed] [Google Scholar]
  60. Silva-Rojas R, Nattarayan V, Jaque-Fernandez F, et al. Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes. Mol Ther 2022; 30 : 868–80. [CrossRef] [PubMed] [Google Scholar]
  61. Li Q, Lin J, Widrick JJ, et al. Dynamin-2 reduction rescues the skeletal myopathy of SPEG-deficient mouse model. JCI Insight 2022; 7 : e157336. [CrossRef] [PubMed] [Google Scholar]
  62. Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014; 6 : 220ra10. [CrossRef] [PubMed] [Google Scholar]
  63. Dudhal S, Mekzine L, Prudhon B, et al. Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations. Mol Ther Nucleic Acids 2022; 29 : 733–48. [CrossRef] [PubMed] [Google Scholar]
  64. CowlingBS, ProkicI, TasfaoutH, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest 2017 ; 127 : 4477–4487. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.